Benzenemethanamine, 3-iodo-N-methyl- | 90389-93-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzenemethanamine, 3-iodo-N-methyl-
• 英文别名: 1-(3-iodophenyl)-N-methylmethanamine
• CAS: 90389-93-8
• 化学式: C₈H₁₀IN
• 分子量: 247.079
• InChiKey: BESWRCDFFVBCRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Benzenemethanamine, 3-iodo-N-methyl- 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 tert-butyl methyl(3-((trimethylsilyl)ethynyl)benzyl)carbamate
  参考文献：
  名称：

  孔中的腈：神经元一氧化氮合酶中一个小的辅助口袋的发现，导致有效和选择性的2-氨基喹啉抑制剂的发展。

  摘要：

  抑制神经元一氧化氮合酶（nNOS）是治疗神经退行性疾病的一种有前途的策略，但是不良的药代动力学通常会阻碍nNOS抑制剂的发展。我们先前开发了一类可透过膜的2-氨基喹啉抑制剂，后来重新排列了支架以减少脱靶结合。但是，与人eNOS相比，所得化合物的通透性降低，人nNOS活性低，选择性低。在这项研究中，合成了5-取代的苯基醚连接的氨基喹啉及其衍生物，并针对纯化的NOS同工型进行了分析。5-氰基化合物是特别有效的和选择性的大鼠和人类nNOS抑制剂。活性和选择性是由氰基与nNOS中新的辅助口袋的结合所介导的。通过喹啉的甲基化和引入简单的手性部分可增强效价，从而产生疏水和辅助口袋效应的组合，从而产生高（约500倍）n / e选择性。重要的是，Caco-2分析还显示了比先前化合物更高的膜通透性。

  DOI：

  10.1021/acs.jmedchem.7b00259
• 作为产物：
  描述：

  在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 Benzenemethanamine, 3-iodo-N-methyl-
  参考文献：
  名称：

  Benzylamines: synthesis and evaluation of antimycobacterial properties

  摘要：

  The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (19, MIC 10.2 micrograms/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 micrograms/mL), and N-butyl-3,5-difluorobenzylamine (103, MIC 6.4 micrograms/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combinations of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

  DOI：

  10.1021/jm00375a005

文献信息

• Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
  申请人：Molino F. Bruce

  公开号：US20060111394A1

  公开（公告）日：2006-05-25

  The present invention relates to a method of treating disorders by administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I): wherein R 1 -R 8 are as described herein, R 4 being aryl or heteroaryl.

  本发明涉及一种通过向需要此类治疗的病人施用式(I)化合物的治疗有效量来治疗疾病的方法： 其中R1-R8如本文所述，R4为芳基或杂芳基。
• [EN] INTERLEUKIN CONVERTING ENZYME AND APOPTOSIS<br/>[FR] ENZYME DE CONVERSION D'INTERLEUKINES ET APOPTOSE
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1997007805A1

  公开（公告）日：1997-03-06

  (EN) The present invention is to the novel compounds of Formula (I), their pharmaceutical compositions, and to the novel inhibition of ICE and ICE-like proteins for use in the treatment of apoptosis, and disease states caused by excessive or inappropriate cell death.(FR) L'invention concerne des composés nouveaux de formule (I), leurs compositions pharmaceutiques et une inhibition nouvelle de protéines de l'enzyme de conversion d'interleukines et de protéines analogues à l'enzyme de conversion d'interleukines destinées à être utilisées pour traiter l'apoptose et les états pathologiques causés par une mort cellulaire excessive ou inappropriée.

  该发明涉及化合物式(I)的新型化合物、它们的药物组合物以及用于治疗由过度或不适当的细胞死亡引起的凋亡和疾病状态的新型ICE和类ICE蛋白的抑制。
• Structure-Based Optimization of Azole Antifungal Agents by CoMFA, CoMSIA, and Molecular Docking
  作者：Chunquan Sheng、Wannian Zhang、Haitao Ji、Min Zhang、Yunlong Song、Hui Xu、Jie Zhu、Zhenyuan Miao、Qingfen Jiang、Jianzhong Yao、Youjun Zhou、Jü Zhu、Jiaguo Lü

  DOI：10.1021/jm051211n

  日期：2006.4.1

  In a continuing effort to develop highly potent azole antifungal agents, the three-dimensional quantitative structure-activity relationship methods. CoMFA and CoMSIA, were applied using a set of novel azole antifungal compounds. The binding mode of the compounds at the active site of lanosterol 14 alpha-demethylase was further explored using the flexible docking method. Various hydrophobic, van der Waals,pi-pi stacking, and hydrogen bonding interactions were observed between the azoles and the enzyme. Based on results from the molecular modeling, a receptor-based pharmacophore model was established to guide the rational optimization of the azole antifungal agents. Thus, a total of 57 novel azoles were designed and synthesized by a three-step optimization process. In vitro antifungal assay revealed that the antifungal activities of these novel azoles were greatly improved, which confirmed the reliability of the model from molecular modeling.
• INTERLEUKIN CONVERTING ENZYME AND APOPTOSIS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0851760A1

  公开（公告）日：1998-07-08
• EP0851760A4
  申请人：——

  公开号：EP0851760A4

  公开（公告）日：1998-11-25